Today, the Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) released the latest results from an ongoing survey that ADLM has been conducting to determine how the Food and Drug Administration's (FDA's) final laboratory developed tests rule will impact patient care. The survey found that, under the FDA rule, individuals from rural and historically marginalized communities will have severely limited access to vital tests, which could lead to harmful and even life-threatening delays in diagnosis and treatment.

AACC has announced that it is changing its name to the Association for Diagnostics & Laboratory Medicine (ADLM).

Recently, the 2021 International Market Briefing & Financial Analyst Briefing held in conjunction with the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo ended successfully in Atlanta, USA.